Prescribing paradigm shift? Applying the 2019 European Society of Cardiology-led guidelines on ‘diabetes, pre-diabetes, and cardiovascular disease’ to assess eligibility for sodium-glucose co-transporter-2 inhibitors or glucagon-like peptide-1 receptor agonists as first-line monotherapy (or add-on to metformin monotherapy) in type 2 diabetes in Scotland

Tom Caparrotta, Luke Blackburn, Stuart McGurnaghan, John Chalmers, Robert Lindsay, Rory McCrimmon, John McKnight, Sarah Wild, John R Petrie, Sam Philip, Paul McKeigue, David Webb, Naveed A. Sattar, Helen Colhoun

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
JournalDiabetes Care
Early online date24 Jun 2020
Publication statusE-pub ahead of print - 24 Jun 2020

Cite this